Evidence map›Paper›PMID 31149423›Full record

ArticleInternational cancer conference journal2016

Dramatic response of chemotherapy for cancer of unknown primary origin of sarcomatoid carcinoma producing granulocyte colony-stimulating factor.

Takahiro Karasuno, Nobuko Nishiura, Maki Kuwayama, Hideki Hattori, Masashi Takeda, Hiroyuki Takamori, Ken Kodama, Yo Sasaki

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in International cancer conference journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Takahiro KarasunoDepartment of Medical Oncology, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka 581-0069 Japan.
Nobuko NishiuraDepartment of Medical Oncology, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka 581-0069 Japan.
Maki KuwayamaDepartment of Hematology, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka 581-0069 Japan.
Hideki HattoriDepartment of Hematology, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka 581-0069 Japan.
Masashi TakedaDepartment of Pathology, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka 581-0069 Japan.
Hiroyuki TakamoriDepartment of Medical Oncology, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka 581-0069 Japan.
Ken KodamaDepartment of Surgery, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka 581-0069 Japan.
Yo SasakiDepartment of Surgery, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka 581-0069 Japan.
Naga Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer of unknown primary origin (CUP) which is usually diagnosed based on the histological type of metastatic site has marked heterogeneous characteristics. Sarcomatoid carcinoma defined as CUP has not been reported according to our literature survey. A 59-year-old man presented with enlarged multiple thoracic lymph nodes, huge splenomegaly and nodules in left temporal lobe of the brain. The histopathological diagnosis of lymph node and spleen was sarcomatoid carcinoma. However, all extensive diagnostic examinations could not detect a site of primary origin. The laboratory data showed marked leukocytosis with increased serum granulocyte colony-stimulating factor (G-CSF). Therefore, the patient was finally diagnosed of CUP of sarcomatoid carcinoma producing G-CSF. After gamma knife treatment for brain metastases, two regimens of taxan-based chemotherapy (carboplatin and paclitaxel, gemcitabine and docetaxel) were administered, with no effect but further tumor progression. Splenectomy for avoiding splenic rupture was performed. As the third line chemotherapy, the combination consisting of doxorubicin and ifosfamide was administered and showed a good therapeutic effect and normalized white blood cell count and serum G-CSF level. He achieved complete remission after three cycles. Herein we present an extremely rare case of CUP of sarcomatoid carcinoma producing G-CSF. Our case suggests the importance of chemotherapy including doxorubicin and ifosfamide, and multimodal therapeutic strategy for this aggressive disease.

Indexed as

Cancer of unknown primary originDoxorubicinGranulocyte colony-stimulating factorIfosfamideSarcomatoid carcinoma

Identifiers

PMID31149423
PMCPMC6498263
OpenAlexW323600184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.